FasoracetamvsPhosphatidylserine

Fasoracetam upregulates GABA-B receptor (GABA-B1/GABA-B2 heterodimer) expression and function, which is unique among racetams — this receptor upregulation is potentially beneficial for restoring GABAergic sensitivity after prolonged benzodiazepine or phenibut use. It enhances group II metabotropic glutamate receptor (mGluR2/mGluR3) signaling, which modulates presynaptic glutamate release and reduces excitotoxicity. Fasoracetam increases acetylcholine release in the cerebral cortex via modulation of choline acetyltransferase activity and vesicular acetylcholine transporter function. It may also modulate the glutamatergic system through mGluR5. The combination of GABAergic (GABA-B-mediated inhibition), glutamatergic (mGluR modulation), and cholinergic enhancement provides anxiolytic effects alongside cognitive enhancement. Clinical trials focus on ADHD patients with GRM (glutamate receptor) gene variants.

PS is a structural component of neuronal membranes, maintaining membrane fluidity and supporting receptor function, ion channel activity, and neurotransmitter release. It localizes preferentially to the inner leaflet of the plasma membrane via flippase enzymes (P4-ATPases), where it serves as a cofactor for protein kinase C (PKC) isoforms alpha, beta, and gamma — PKC activation phosphorylates substrates including MARCKS and GAP-43, critical for synaptic plasticity and memory consolidation. PS modulates the HPA axis via glucocorticoid receptor feedback, reducing cortisol by 15-30% in stressed individuals. It facilitates choline transport via high-affinity choline transporter (CHT1) into presynaptic terminals, supporting acetylcholine synthesis by choline acetyltransferase. PS also regulates NMDA receptor function and supports Na+/K+-ATPase activity. Downstream, PS enhances CREB phosphorylation and BDNF expression in hippocampal neurons.